Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294884 | 0.67 | MAPK1 (0.44) | ALOX12LMNAMAPK1TSHRKDM4E | |
| SCHEMBL30832576 | 0.65 | MAPK1 (0.41) | ALOX12LMNARECQLMAPK1TSHR | |
| SCHEMBL30832579 | 0.65 | MAPK1 (0.41) | ALOX12LMNARECQLMAPK1TSHR | |
| SCHEMBL30832575 | 0.65 | MAPK1 (0.41) | ALOX12LMNARECQLMAPK1TSHR | |
| Alpha-Pinene SCHEMBL6662443 | 0.62 | TSHR (0.81) | ALOX12LMNARECQLMAPK1TSHR | |
| SCHEMBL716586 | 0.62 | KCNH2 (0.58) | MAPK1TSHRKDM4EHTTTDP1 | |
| SCHEMBL30832580 | 0.62 | MAPK1 (0.53) | ALOX12LMNAMAPK1TSHRKDM4E | |
| SCHEMBL30832585 | 0.62 | MAPK1 (0.53) | ALOX12LMNAMAPK1TSHRKDM4E | |
| Acetic Acid SCHEMBL30496778 | 0.62 | TSHR (0.46) | MAPK1TSHRKDM4EHTTTDP1 | |
| Myrtenol SCHEMBL15536292 | 0.60 | TSHR (0.58) | MAPK1TSHRKDM4EHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | CNR1, CNR2, ADRA2C | ALOX12 1310/4885LMNA 1454/4885RECQL 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.